SKP2 E3 Ligase Inhibitor IV

A cell-permeable dimethylanilinomethylamine compound that inhibits SKP2-dependent cellular p27^Kip1 ubiquitination activity (10 to 30 µM; 16 h; in MM1.S myeloma and HeLa cultures) by preventing the incorporation of SKP2 into the Skp1-cullin1-F-box/SCF complex. Selectively induces the accumulation of known SCF^SKP2 substrates (p21^Cip1, p27^Kip1, and p57^Kip2) in multiple myeloma RPMI 8226 cells, without inducing HSP-27 phosphorylation or affecting cellular levels of Fbw7 and β-TrCP substrates (c-Jun and β-catenin, respectively) seen with proteasome inhibition by Bortezomib (Cat. No. 504314 ) treatment. Shown to exhibit antiproliferation activity against 13 myeloma lines (GI₅₀ in 3 d from 4.2 to 13.2 µM), including melphalan-, doxorubicin- and steroid-resistant clones, via autophage-initiated cell death induction in a caspase-3-independent manner, and exhibit cancer-selective cytotoxicity against primary CD138⁺ malignant cells vs. CD138^- nonneoplastic blood cells from MM patient blood (viability in 24 h with/without 5 µM drug treatment = 1.38%/66.4% for CD138⁺ vs. 81.3%/94% CD138^-).

Cell permeable: yes

Primary Target
Skp1/Skp2 interaction

Reversible: yes

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Use only fresh DMSO for reconstitution.

Chen, Q., et al. 2008. Blood111, 4690.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)